IFNg SMC: A New Approach to Mesenchymal Stem Cell Therapy

Cellular therapies have demonstrated great promise and exceptional safety profiles in clinical trials. However, except for a subset of autologous therapies, manufactured at small scale, regulatory approval and wide commercial success has been lacking for allogeneic products for treatment of large patient populations. Issues impeding success include high costs of production, low scalability, low or variable control of manufacturing parameters, causing lot-to-lot variation, and complex cold-chain logistics.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 197 Source Type: research